155 related articles for article (PubMed ID: 7715897)
1. Pretargetted imaging of colorectal cancer recurrences using an 111In-labelled bivalent hapten and a bispecific antibody conjugate.
Chetanneau A; Barbet J; Peltier P; Le Doussal JM; Gruaz-Guyon A; Bernard AM; Resche I; Rouvier E; Bourguet P; Delaage M
Nucl Med Commun; 1994 Dec; 15(12):972-80. PubMed ID: 7715897
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
Barbet J; Peltier P; Bardet S; Vuillez JP; Bachelot I; Denet S; Olivier P; Leccia F; Corcuff B; Huglo D; Proye C; Rouvier E; Meyer P; Chatal JF
J Nucl Med; 1998 Jul; 39(7):1172-8. PubMed ID: 9669389
[TBL] [Abstract][Full Text] [Related]
3. In-111 CYT-103 monoclonal antibody imaging in patients with suspected recurrent colorectal cancer.
Doerr RJ; Herrera L; Abdel-Nabi H
Cancer; 1993 Jun; 71(12 Suppl):4241-7. PubMed ID: 8508386
[TBL] [Abstract][Full Text] [Related]
4. Pre-clinical and clinical studies of two new bifunctional chelating agents for immunoscintigraphy with 111In-anti-CEA monoclonal antibody.
Faivre-Chauvet A; Mease RC; Chetanneau A; Bardiès M; Sai-Maurel C; Meinken GE; Srivastava SC; Chatal JF; Gestin JF
Nucl Med Commun; 1996 Sep; 17(9):781-9. PubMed ID: 8895905
[TBL] [Abstract][Full Text] [Related]
5. Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer.
Vuillez JP; Moro D; Brichon PY; Rouvier E; Brambilla E; Barbet J; Peltier P; Meyer P; Sarrazin R; Brambilla C
J Nucl Med; 1997 Apr; 38(4):507-11. PubMed ID: 9098191
[TBL] [Abstract][Full Text] [Related]
6. Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response.
Le Doussal JM; Chetanneau A; Gruaz-Guyon A; Martin M; Gautherot E; Lehur PA; Chatal JF; Delaage M; Barbet J
J Nucl Med; 1993 Oct; 34(10):1662-71. PubMed ID: 8410279
[TBL] [Abstract][Full Text] [Related]
7. Use of the radiolabeled murine monoclonal antibody, 111In-CYT-103, in the management of colon cancer.
Petersen BM; Bass BL; Bates HR; Chandeysson PL; Harmon JW
Am J Surg; 1993 Jan; 165(1):137-42; discussion 142-3. PubMed ID: 8418688
[TBL] [Abstract][Full Text] [Related]
8. [Indium 111-labeled antibodies in the detection of colorectal carcinoma].
Artiko V; Obradović V; Davidović B; Petrović N; Petrović M; Krivokapić Z; Pavlov M; Adanja G; Sobić D; Vlajković M; Pavlović S; Rebić R
Acta Chir Iugosl; 2003; 50(4):43-6. PubMed ID: 15307496
[TBL] [Abstract][Full Text] [Related]
9. 111In-CYT-103 scanning in recurrent colorectal cancer--does it affect standard management?
Dominguez JM; Wolff BG; Nelson H; Forstrom LA; Mullan BP
Dis Colon Rectum; 1996 May; 39(5):514-9. PubMed ID: 8620800
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunodetection of colorectal carcinoma.
Artiko V; Obradovic V; Davidovic B; Petrovic N; Petrovic M; Krivokapic Z; Kecmanovic D; Pesko P; Djukic V; Milosavljevic T; Adanja G; Vlajkovic M
Hepatogastroenterology; 2003; 50(52):1029-31. PubMed ID: 12845972
[TBL] [Abstract][Full Text] [Related]
11. FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma.
Willkomm P; Bender H; Bangard M; Decker P; Grünwald F; Biersack HJ
J Nucl Med; 2000 Oct; 41(10):1657-63. PubMed ID: 11037995
[TBL] [Abstract][Full Text] [Related]
12. Planar, SPET and three-dimensional immunoscintigraphy of suspected recurrent colorectal cancer using 111In-B72.3 (Oncoscint CR-OV): effect of administered activity.
Perkins AC; Vincent RM; Wastie ML; Denton GW; Amar S; Hardcastle JD
Nucl Med Commun; 1994 Dec; 15(12):981-90. PubMed ID: 7715898
[TBL] [Abstract][Full Text] [Related]
13. Imaging with indium111-labeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases.
Patt YZ; Lamki LM; Shanken J; Jessup JM; Charnsangavej C; Ajani JA; Levin B; Merchant B; Halverson C; Murray JL
J Clin Oncol; 1990 Jul; 8(7):1246-54. PubMed ID: 2193120
[TBL] [Abstract][Full Text] [Related]
14. [111-indium DTPA octreotide scintigraphy in colorectal liver metastases].
Seifert JK; Görges R; Bockisch A; Junginger T
Langenbecks Arch Chir; 1997; 382(6):332-6. PubMed ID: 9498205
[TBL] [Abstract][Full Text] [Related]
15. Initial clinical study of indium-111-labeled clone 110 anticarcinoembryonic antigen antibody in patients with colorectal cancer.
Griffin TW; Brill AB; Stevens S; Collins JA; Bokhari F; Bushe H; Stochl MC; Gionet M; Rusckowski M; Stroupe SD
J Clin Oncol; 1991 Apr; 9(4):631-40. PubMed ID: 2066759
[TBL] [Abstract][Full Text] [Related]
16. Immunoscintigraphy with 99Tcm-labelled monoclonal anti-CEA BW 431/26 antibodies in patients with suspected recurrent and metastatic colorectal carcinoma: two-year follow-up.
Lacić M; Bokulić T; Lukac J; Baum RP; Kusić Z
Nucl Med Commun; 1999 Sep; 20(9):859-65. PubMed ID: 10533193
[TBL] [Abstract][Full Text] [Related]
17. Detection of colorectal carcinoma by anti-CEA monoclonal antibody (IOR-CEA1) labeled with 99mTc scintigraphy.
Sirisriro R; Boonkitticharoen V; Kraiphibul P; Ratanatharathorn V; Sumboonnanon K; Kanjanapitak A; Kuhapremma T; Sritara C; Puchinda D; Chouplywech P; Jalayondeja V; Pekanan P; Rochanawutanon M; Intaramarn C; Ayudhya AN; Chokesuwathana P
Hepatogastroenterology; 2000; 47(32):405-13. PubMed ID: 10791201
[TBL] [Abstract][Full Text] [Related]
18. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
[TBL] [Abstract][Full Text] [Related]
19. Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-diethylenetriaminepentaacetic acid F(ab')2 antibody.
Aarts F; Boerman OC; Sharkey RM; Hendriks T; Chang CH; McBride WJ; Bleichrodt RP; Oyen WJ; Goldenberg DM
Cancer; 2010 Feb; 116(4 Suppl):1111-7. PubMed ID: 20127959
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.
Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thédrez P; Fiche M; Gautherot E; Barbet J; Chatal JF
J Nucl Med; 1998 Sep; 39(9):1608-13. PubMed ID: 9744353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
